The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer

Cancers

Kenneth J. Oɻyrne¹  Martin P. Barr¹ 

[1] Trinity College Dublin, Department of Clinical Medicine, Trinity Centre for Health Sciences, St James Hospital, James Street, Dublin 8, Ireland;

关键词: epigenetics;    histone;    post-translational modification;    DNA methylation;    epigenetic modifiers;    cisplatin;    NSCLC;   

DOI  :  10.3390/cancers3011426

来源: mdpi

【 摘 要 】

Non-small cell lung cancer (NSCLC) is the most common cause of cancer related death in the world. Cisplatin and carboplatin are the most commonly used cytotoxic chemotherapeutic agents to treat the disease. These agents, usually combined with drugs such as gemcitabine or pemetrexed, induce objective tumor responses in only 20–30% of patients. Aberrant epigenetic regulation of gene expression is a frequent event in NSCLC. In this article we review the emerging evidence that epigenetics and the cellular machinery involved with this type of regulation may be key elements in the development of cisplatin resistance in NSCLC.

【 授权许可】

CC BY   
© 2011 by the authors; licensee MDPI, Basel, Switzerland.